Guo, Christina
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Funding for this research was provided by:
Cancer Research UK
Biomedical Research Centre Grant NIHR NIHR Research Professorship award
Article History
Received: 24 December 2020
Revised: 23 February 2021
Accepted: 11 March 2021
First Online: 15 April 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: U.B. has received funding for the investigator-initiated clinical trial discussed in the manuscript from Chugai Pharmaceuticals and Verastem Oncology. U.B. has also received funding from Verastem Oncology for preclinical research. U.B. is an employee of The Institute of Cancer Research that has commercial interests in the development of RAF inhibitors.
: The authors acknowledge funding from the Experimental Cancer Medicine Centre and Biomedical Research Centre to the Institute of Cancer Research and the Royal Marsden Hospital NHS foundation trust. U.B. also acknowledges funding from CRUK and the NIHR.